 |
 |
Excerpt from the December 1996 Parkinson's Action Network "Action Reporter", an Advocacy Report for the Parkinson's Community- 1996 Has Been Landmark Year in Parkinson's Research >From basic research into the cause to clinical trials of new therapies, this was a landmark year in the quest to understand-and conquer-Parkinson's disease. September saw the initiation of the first human trials of Glial Cell Line-Derived Neurotrophic Factor in people with Parkinson's. The international biotechnology company AMGEN announced that these trials will last 12-15 months, and be used to evaluate the safety and tolerability of GDNF in patients with moderate to severe Parkinson's. "We are pleased that the first human trial of this important therapeutic is now underway," said Gordon Binder, AMGEN's chairman and CEO. "We hope that GDNF will provide patients and health care providers with a more effective treatment option." Not surprisingly, there has been a tremendous interest in these trials and updated information will be published as soon as it is made available. If you have any questions or comments regarding the scientific research described here, please contact PAN at (800) 850-4726 Parkinson's Action Network 800-850-4726 Headquarters: 818 College Ave., Suite C Santa Rosa, CA 95404 phone 707-544-1994 fax 707-544-2363 email: [log in to unmask] Washington, DC office 601 13th St. NW., Suite 310 Washington, DC 20005 phone 202-628-2079 fax 202-628-2077 Brad Udall, Chair Joan I. Samuelson, President John L. Dodge, Treasurer Bonnie K. Mioduchoski, Administrator Michael Claeys, Community Coordinator The Action Reporter is a free publication of the Parkinson's Action Network, a non-profit charitable foundation for a cure for Parkinson's. Use of this material in other publications is welcomed. We ask that the Network be identified as the source of the material, and notified how, when and where the material is used. Simply call 800-850-4726